Review - Beyond Bioethics: Toward a New Biopolitics
By Jordan Liz,
Metapsychology Online Reviews [Review of the book edited by CGS' Osagie K Obasogie and Marcy Darnovsky]
| 09. 04. 2018
From the successful cloning of Dolly the sheep, to the FDA's approval of BiDil as the first race-specific medication to ongoing discussions concerning the use of gene editing technologies such as "CRISPR," medical innovations during the past couple of decades have raised a number of significant ethical, social and political questions. Should cloning as human reproduction be limited? Is the pursuit of race-based medicine morally acceptable? Would it be a moral failure to abstain from using gene-editing technologies if they are proven safe to use? For Osagie K. Obasogie and Marcy Darnovsky, the editors of Beyond Biopolitics: Toward a New Bioethics, these questions are further complicated by the specific sociopolitical context in which they arise. How do we understand, for instance, the FDA's approval of BiDil alongside the history of race and eugenics in the United States? Addressing these questions requires, on their account, a conceptual framework and approach not found in contemporary bioethics.
To elaborate, for Obasogie and Darnovsky, bioethics currently operates on the basis of principlism. Principlism "provides a common framework by embracing four principles as...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...